Sotera Health Company (SHC) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
21 May, 2026Opening remarks and agenda
Meeting opened with a welcome and reminder about forward-looking statements and associated risks and uncertainties.
Board members and key participants, including the independent auditor, were introduced.
Agenda and meeting materials were made available to participants, and the three main proposals were outlined: election of directors, advisory vote on executive compensation, and ratification of the auditor.
Board and executive committee updates
Recognition was given to outgoing board members for their service.
Board composition highlighted diverse expertise in management, finance, strategy, and healthcare.
Shareholder proposals
Three proposals presented: election of four directors for a three-year term, advisory approval of executive compensation, and ratification of Ernst & Young LLP as auditor for 2026.
No additional nominations were received; nominations were closed per bylaws.
Latest events from Sotera Health Company
- Q2 2026 revenue up 9.2%, net income $53.6M, margin 51.6%, and outlook raised.SHC
Q2 2026 - Strong 2025 outlook with stable operations, regulatory-driven consolidation, and disciplined growth.SHC
Jefferies Global Healthcare Conference 2025 - Growth accelerates, modernization advances, and M&A focus sharpens amid effective risk management.SHC
Wolfe Research Healthcare Conference 2025 - CEO transition, regulatory investments, and global expansion drive growth and resilience.SHC
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Leadership transition, steady growth, and robust supply chain investments drive positive outlook.SHC
Jefferies Global Healthcare Conference 2026 - Strong demand, margin recovery, and new leadership drive positive outlook for the year.SHC
RBC Capital Markets Global Healthcare Conference 2026 - Targeting 5%-7% annual growth and $500M+ free cash flow by 2027, driven by strategic priorities.SHC
Investor Day 2024 - Q1 2025 revenue and EBITDA grew, but net loss resulted from a $31M EO litigation settlement.SHC
Q1 2025 - 2025 guidance targets 4%-6% revenue growth, margin expansion, and lower CapEx amid FX risks.SHC
Q4 2024